Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Maria Gonzalez-Cao"'
Autor:
Irene Moya, Beatriz García Pelaez, Andrés Aguilar, Laura Berrocal, Santiago Viteri, Maria Gonzalez Cao, Sonia Rodríguez, Marta Vives-Usano, Maria José Catalán, Erika Aldeguer, Francesc Pons, Alejandro Martinez-Bueno, Mónica Garzón Ibañez, Clara Mayo de las Casas, Nuria Jordana, Miguel Angel Molina, Ruth Román Lladó, Juan José García-Mosquera, Rafael Rosell, Carlos Cabrera, Ekaterina Meshoulam
Publikováno v:
Journal of Molecular Pathology
Volume 2
Issue 2
Pages 13-134
Journal of Molecular Pathology, Vol 2, Iss 13, Pp 123-134 (2021)
Volume 2
Issue 2
Pages 13-134
Journal of Molecular Pathology, Vol 2, Iss 13, Pp 123-134 (2021)
Somatic copy number variations (CNV
i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered
i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered
Autor:
Michaela Müller-Trutwin, Valérie Monceaux, Montse Jimenez, Lorna Leal, Nicolas Huot, Maria Gonzalez-Cao, Victoria González-Soler, Maria Cristina O. Salgado, Asier Sáez-Cirión, Cristina Gálvez, Judith Dalmau, Julià Blanco, Victor Urrea, Felipe García, Javier Martinez-Picado, Bonaventura Clotet
Publikováno v:
EBioMedicine
EBioMedicine, 2020, 57, pp.102830. ⟨10.1016/j.ebiom.2020.102830⟩
EBioMedicine, Vol 57, Iss, Pp 102830-(2020)
EBioMedicine, Elsevier, 2020, 57, pp.102830. ⟨10.1016/j.ebiom.2020.102830⟩
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
EBioMedicine, 2020, 57, pp.102830. ⟨10.1016/j.ebiom.2020.102830⟩
EBioMedicine, Vol 57, Iss, Pp 102830-(2020)
EBioMedicine, Elsevier, 2020, 57, pp.102830. ⟨10.1016/j.ebiom.2020.102830⟩
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Altres ajuts: This research was sponsored in part by Grifols and by Merck Sharp & Dohme España, S.A. (IISP 54925). The funding organizations had no input in the design of the study; in the collection, analyses, or interpretation of the data; writing
Autor:
Silvia Muñoz, William P.J. Leenders, A. Aguilar-Hernández, Luis M. Montuenga, Roxana Reyes, Maria Gonzalez-Cao, R. Roman, Elena Gonzalvo, Cristina Sainz, Cristina Teixidó, Andrés F. Cardona, Maria D. Lozano, Elba Marin, Ainara Arcocha, Carlos R. Cabrera, Miguel Mesa-Guzman, Aleix Prat, Miguel Angel Molina-Vila, I. Sullivan, Cristina Aguado, Alejandro Martinez-Bueno, Erika Aldeguer, Irene Moya, Ramon Palmero, Noemi Reguart, Rafael Rosell, Laura López-Vilaró, Ana Giménez-Capitán, Santiago Viteri, Sonia Rodríguez, Sergi Castillo, Nuria Viñolas
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Molecular Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Fundacion Sancho el Sabio Fundazioa (FSS)
Molecular Oncology, Vol 15, Iss 2, Pp 350-363 (2021)
Molecular Oncology, 15, 350-363
Scientia
Molecular Oncology, 15, 2, pp. 350-363
Universitat Autònoma de Barcelona
Molecular Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Fundacion Sancho el Sabio Fundazioa (FSS)
Molecular Oncology, Vol 15, Iss 2, Pp 350-363 (2021)
Molecular Oncology, 15, 350-363
Scientia
Molecular Oncology, 15, 2, pp. 350-363
We studied MET alterations in 474 advanced non‐small‐cell lung cancer (NSCLC) patients by nCounter, an RNA‐based technique. We identified 3% with METΔex14 mRNA and 3.5% with very‐high MET mRNA expression, a surrogate of MET amplification. ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c00b42c81cc41a7f2eb1ec563f3b10
https://ddd.uab.cat/record/238801
https://ddd.uab.cat/record/238801
Autor:
Maria Gonzalez Cao, Elisa Giovannetti, Alessandro D'Aveni, Maria Grazia Daffinà, Niki Karachaliou, Alessia Liguori, Rafael Rosell, Giuseppe Altavilla, Mariacarmela Santarpia, Grazia Marabello
Publikováno v:
Drug design, development and therapy 11 (2017): 2047–2063. doi:10.2147/DDDT.S113500
info:cnr-pdr/source/autori:Santarpia M.; Daffina M.G.; D'Aveni A.; Marabello G.; Liguori A.; Giovannetti E.; Karachaliou N.; Cao M.G.; Rosell R.; Altavilla G./titolo:Spotlight on ceritinib in the treatment of ALK+ NSCLC: Design, development and place in therapy/doi:10.2147%2FDDDT.S113500/rivista:Drug design, development and therapy/anno:2017/pagina_da:2047/pagina_a:2063/intervallo_pagine:2047–2063/volume:11
Drug Design, Development and Therapy, Vol Volume 11, Pp 2047-2063 (2017)
Santarpia, M, Daffinà, M G, D’Aveni, A, Marabello, G, Liguori, A, Giovannetti, E, Karachaliou, N, Cao, M G, Rosell, R & Altavilla, G 2017, ' Spotlight on ceritinib in the treatment of ALK+ NSCLC : Design, development and place in therapy ', Drug Design, Development and Therapy, vol. 11, pp. 2047-2063 . https://doi.org/10.2147/DDDT.S113500
Drug Design, Development and Therapy
info:cnr-pdr/source/autori:Santarpia M.; Daffina M.G.; D'Aveni A.; Marabello G.; Liguori A.; Giovannetti E.; Karachaliou N.; Cao M.G.; Rosell R.; Altavilla G./titolo:Spotlight on ceritinib in the treatment of ALK+ NSCLC: Design, development and place in therapy/doi:10.2147%2FDDDT.S113500/rivista:Drug design, development and therapy/anno:2017/pagina_da:2047/pagina_a:2063/intervallo_pagine:2047–2063/volume:11
Drug Design, Development and Therapy, Vol Volume 11, Pp 2047-2063 (2017)
Santarpia, M, Daffinà, M G, D’Aveni, A, Marabello, G, Liguori, A, Giovannetti, E, Karachaliou, N, Cao, M G, Rosell, R & Altavilla, G 2017, ' Spotlight on ceritinib in the treatment of ALK+ NSCLC : Design, development and place in therapy ', Drug Design, Development and Therapy, vol. 11, pp. 2047-2063 . https://doi.org/10.2147/DDDT.S113500
Drug Design, Development and Therapy
Mariacarmela Santarpia,1 Maria Grazia Daffinà,1 Alessandro D’Aveni,1 Grazia Marabello,1 Alessia Liguori,1 Elisa Giovannetti,2–4 Niki Karachaliou,5 Maria Gonzalez Cao,6 Rafael Rosell,7,8 Giuseppe Altavilla1 1Medical Oncology Unit, Department of H
Autor:
Aaron E. Sosa, Mariacarmela Santarpia, Jordi Berenguer, Niki Karachaliou, Rafael Rosell, Giuseppe Altavilla, Cristina Teixidó, Maria Gonzalez Cao, Alejandra Rodriguez Capote
Publikováno v:
Expert Opinion on Investigational Drugs
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction: Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over standard platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients. The
Autor:
Danilo Rocco, Niki Karachaliou, Clara Mayo de-las-Casas, Alejandro Martinez-Bueno, Roberta Sgariglia, Pasquale Pisapia, Umberto Malapelle, Claudio Bellevicine, Francesco Pepe, Rafael Rosell, Caterina De Luca, Miguel Angel Molina-Vila, Daniela Morales-Espinosa, Giancarlo Troncone, Mónica Garzón, Maria Giovanna Russo, Maria Gonzalez-Cao, Santiago Viteri Ramirez, Núria Jordana-Ariza
Publikováno v:
British Journal of Cancer
Background: When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relev
Autor:
Niki Karachaliou, Cristina Teixidó, Miguel Angel Molina-Vila, Ariadna Balada, Mónica Garzón, Clara Mayo de las Casas, Maria Gonzalez-Cao, Santiago Viteri Ramirez, Nuria Jordana Ariza, Rafael Rosell, Daniela Morales-Espinosa
Publikováno v:
Translational Lung Cancer Research. 5:532-537
Genomic analysis of circulating tumor DNA (ctDNA) released from cancer cells into the bloodstream has been proposed as a useful method to capture dynamic changes during the course of the disease. In particular, the ability to monitor epidermal growth
Autor:
Giancarlo Troncone, Umberto Malapelle, Santiago Viteri-Ramirez, Clara Mayo-de-las-Casas, Noemí Reguart, Niki Karachaliou, Ariadna Balada-Bel, Maria José Catalán, Ana Blasco, Beatriz García-Peláez, Alejandro Martinez-Bueno, Núria Jordana-Ariza, Mónica Garzón-Ibáñez, Rafael Rosell, Raquel Campos, Sergio Villatoro, Miguel Angel Molina-Vila, Irene Moya-Horno, R. Blanco, Maria Gonzalez-Cao, Margarita Majem, Xavier Gonzalez
Publikováno v:
Molecular Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Molecular Oncology, Vol 13, Iss 12, Pp 2633-2645 (2019)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Molecular Oncology, Vol 13, Iss 12, Pp 2633-2645 (2019)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74031d25b8b6b6755deee5fc272706e0
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2889
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2889
Autor:
Juan José García-Mosquera, Andrés Aguilar, Santiago Viteri, Niki Karachaliou, Rafael Rosell, Maria Gonzalez-Cao
Publikováno v:
Cancer Cell
Summary Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3236406b4150faea389ef8468e7c55a7
https://europepmc.org/articles/PMC6328696/
https://europepmc.org/articles/PMC6328696/
Autor:
Maria Gonzalez Cao, Sònia Pedreño-López, Cristina Teixidó, Roberto Martinez, Gustavo Tapia, Silvia De Muga, Alba Hernández, Julià Blanco, Bonaventura Clotet, Luis Ibarz, Cecilia Cabrera, Elisabet García, Victor Urrea
Publikováno v:
OncoImmunology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
OncoImmunology, Vol 8, Iss 8 (2019)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
OncoImmunology, Vol 8, Iss 8 (2019)
Intravesical Bacille Calmette-Guerin (BCG) remains the most effective treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), unfortunately there is no validated biomarker to predict clinical outcome. Here we tried to explore the possibil